Constance Keyserling
Geschäftsführer bei ABIONYX PHARMA
Aktive Positionen von Constance Keyserling
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ABIONYX PHARMA | Geschäftsführer | - | - |
Corporate Officer/Principal | - | - |
Karriereverlauf von Constance Keyserling
Ehemalige bekannte Positionen von Constance Keyserling
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
PFIZER, INC. | Corporate Officer/Principal | - | - |
ESPERION THERAPEUTICS, INC. | Geschäftsführer | - | - |
Parke, Davis & Co. LLC | Corporate Officer/Principal | - | - |
QuatRx Pharmaceuticals Co.
QuatRx Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology QuatRx Pharmaceuticals Co. manufactures and develops therapeutic compounds. Its clinical products, ospemifene and fispemifene, treat hormone deficiencies that result from aging in women and men. The firm's preclinical program is designed to address sex steroid dependent diseases through inhibition of 17beta- hydroxysteroid dehydrogenase (HSD) enzymes. The company was founded by Robert Zerbe, Christopher Nicholas, and Stuart Dombey on November 20 2000 and is headquartered in Ann Arbor, MI. | Corporate Officer/Principal | - | - |
Ausbildung von Constance Keyserling
Harvard University | Graduate Degree |
Statistik
International
Vereinigte Staaten | 6 |
Frankreich | 2 |
Operativ
Corporate Officer/Principal | 4 |
Chief Operating Officer | 2 |
Graduate Degree | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
ABIONYX PHARMA | Health Technology |
ESPERION THERAPEUTICS, INC. | Health Technology |
PFIZER, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
QuatRx Pharmaceuticals Co.
QuatRx Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology QuatRx Pharmaceuticals Co. manufactures and develops therapeutic compounds. Its clinical products, ospemifene and fispemifene, treat hormone deficiencies that result from aging in women and men. The firm's preclinical program is designed to address sex steroid dependent diseases through inhibition of 17beta- hydroxysteroid dehydrogenase (HSD) enzymes. The company was founded by Robert Zerbe, Christopher Nicholas, and Stuart Dombey on November 20 2000 and is headquartered in Ann Arbor, MI. | Health Technology |
Parke, Davis & Co. LLC |
- Börse
- Insiders
- Constance Keyserling
- Erfahrung